Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore

Prostate Specific Antigen (PSA)-based prostate cancer (CaP) screening is beneficial in terms of mortality reduction, however its main drawbacks are overdiagnosis and overtreatment of indolent CaP [1]. A more and more used strategy to limit overtreatment of indolent CaP cancer is the use of active surveillance as initial treatment [2]. To improve screening efforts further, a balance must be found between minimizing overdiagnosis, and optimizing the timely detection of potentially deadly disease [3].

Source: Urologic Oncology: Seminars and Original Investigations - December 6, 2018 Category: Urology & Nephrology Authors: Jan F.M. Verbeek, Chris H. Bangma, Charlotte F. Kweldam, Theodorus H. van der Kwast, Intan P. K ümmerlin, Geert J.L.H. van Leenders, Monique J. Roobol Tags: Clinical-Prostate cancer Source Type: research